We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-3 of 3

Industry stakeholders offer input on FDA’s draft guidances on off-label communications
  • Loeb & Loeb LLP
  • USA
  • May 30 2017

Industry stakeholders are weighing in on the two draft guidances issued by the FDA outlining how drug and device companies can discuss off-label uses


Industry groups say final rule on intended use establishes unfounded legal standard, call for indefinite stay
  • Loeb & Loeb LLP
  • USA
  • February 27 2017

Citing violations of the APA and what they call the establishment of a "new and unjustified legal standard," a coalition of industry groups is


FDA finalizes rule on citizen petitions delaying generic approvals; declines PhRMA requests
  • Loeb & Loeb LLP
  • USA
  • November 29 2016

He final rule makes clear that the FDA will not delay the approval of pending ANDA, 505(b)(2) or 351(k) applications because of citizen petitions